• © 2009 by American Society of Clinical Oncology

ERRATA

The June 20, 2009, article by Bottomley et al, entitled, “Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group” (J Clin Oncol 27:2916–2923, 2009), contained an error.

In the Methods section of the Abstract, the induction and maintenance doses for PEG-IFN-α-2b were given as 6 g/kg/wk and 3 g/kg/wk, respectively, whereas they should have been 6 μg/kg/wk and 3 μg/kg/wk, respectively, as follows:

“A total of 1,256 patients with stage III melanoma were randomly assigned after full lymphadenectomy to receive either observation (n = 629) or PEG-IFN-α -2b (n = 627): induction 6 μg/kg/wk for 8 weeks then maintenance 3 μg/kg/wk for an intended total duration of 5 years.”

The online version has been corrected in departure from the print.